Aspirin (acetylsalicylic acid)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ASPIRIN |
|---|---|
| Type | Drug |
| Aliases | AspirinBayer AspirinCardiomagnylАцетилсаліцилова кислота |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ET DIS-PV |
| Sources | SRC-NCCN-MM-2025 |
Drug Facts
| Class | Non-selective cyclooxygenase (COX-1/COX-2) inhibitor; antiplatelet at low dose |
|---|---|
| Mechanism | Irreversibly acetylates serine-530 of platelet COX-1, blocking thromboxane A2 synthesis for the platelet's lifespan (~7-10 days). At low antiplatelet doses (75-325 mg) produces selective inhibition of platelet aggregation without significant anti-inflammatory effect. |
| Typical dosing | 81-100 mg PO daily for VTE prophylaxis in low-risk lenalidomide-treated patients |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Standard VTE prophylaxis for lenalidomide-treated MM patients without additional VTE risk factors. For higher-risk patients (prior VTE, immobility, central venous catheter, active disease at induction) switch to LMWH (enoxaparin 40 mg SC daily) or apixaban. Hold aspirin if platelets <50K.
Used By
Indications
IND-PV-ANAGRELIDE-CONTINUOUS- IND-PV-ANAGRELIDE-CONTINUOUSIND-PV-PREGNANCY-PEG-IFN- IND-PV-PREGNANCY-PEG-IFN
Regimens
REG-HU-PV-ET- Hydroxyurea (PV / ET high-risk 1L cytoreduction) + baseline phlebotomy/ASAREG-ROPEGINTERFERON-PV- Ropeginterferon alfa-2b (Besremi) for PV — 1L cytoreductiveREG-RUX-PV- Ruxolitinib (PV — HU-resistant / intolerant)
Supportive Care
SUP-MM-VTE-PROPHYLAXIS- VTE prophylaxis for IMiD-based myeloma therapy